Data gathered: September 13
Alternative Data for TransCode Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,646 | Sign up | Sign up | Sign up |
| Twitter Followers | 296 | Sign up | Sign up | Sign up |
| Twitter Mentions | 17 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 12 | Sign up | Sign up | Sign up |
About TransCode Therapeutics
TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes.
| Price | $0.25 |
| Target Price | Sign up |
| Volume | 275,160 |
| Market Cap | $4.5M |
| Year Range | $0.23 - $5.92 |
| Dividend Yield | 0% |
| PE Ratio | 0 |
| Industry | Biotechnology |
In the news
 |
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic CancerSeptember 9 - Yahoo |
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate?s Preclinical Efficacy Against Metastatic CancerSeptember 9 - GlobeNewswire |
|
 |
TransCode Therapeutics (NASDAQ:RNAZ) Earns Buy Rating from HC WainwrightSeptember 9 - ETF Daily News |
Buy Rating for TransCode Therapeutics Backed by NIH Grant and Promising Treatment EfficacySeptember 4 - TipRanks |
|
|
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead CandidateSeptember 4 - Yahoo |
TransCode Therapeutics secures $2M grant for lead candidateSeptember 4 - Seeking Alpha |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 0 | 2M | -2.1M | -5.2M | 0 | -0.720 |
| Q1 '24 | 750,000 | 1.5M | -1.6M | -3.3M | -3.9M | -22.840 |
| Q4 '23 | 0 | 1.1M | -1.2M | -4M | 0 | -22.840 |
| Q3 '23 | 0 | 2M | -2M | -5.3M | -5.2M | -1.680 |
| Q2 '23 | 0 | 2.2M | -2.2M | -4.3M | -4.2M | -3.290 |
Insider Transactions View All
| Dudley Robert Michael filed to buy 180,262 shares at $0.5. October 2 '23 |
| Fitzgerald Thomas A filed to buy 56,318 shares at $0.5. October 2 '23 |
| Dudley Robert Michael filed to buy 82,262 shares at $2.7. June 22 '23 |
| Dudley Robert Michael filed to buy 70,262 shares at $2.5. June 22 '23 |
| Dudley Robert Michael filed to buy 912,114 shares at $2.8. June 13 '23 |
Similar companies
Read more about TransCode Therapeutics (RNAZ) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of TransCode Therapeutics?
The Market Cap of TransCode Therapeutics is $4.5M.
What is TransCode Therapeutics' PE Ratio?
As of today, TransCode Therapeutics' PE (Price to Earnings) ratio is 0.
What is the current stock price of TransCode Therapeutics?
Currently, the price of one share of TransCode Therapeutics stock is $0.25.
How can I analyze the RNAZ stock price chart for investment decisions?
The RNAZ stock price chart above provides a comprehensive visual representation of TransCode Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling TransCode Therapeutics shares. Our platform offers an up-to-date RNAZ stock price chart, along with technical data analysis and alternative data insights.
Does RNAZ offer dividends to its shareholders?
As of our latest update, TransCode Therapeutics (RNAZ) does not offer dividends to its shareholders. Investors interested in TransCode Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of TransCode Therapeutics?
Some of the similar stocks of TransCode Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.